Helix BioPharma Corp HBPCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.71
- Day Range
- $0.77–1.71
- 52-Week Range
- $0.77–1.73
- Bid/Ask
- $0.00 / $1.71
- Shares Outstanding
- 76.38M
- Market Cap
- $58.81M
- Volume/Avg
- 200 / 820
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Helix BioPharma Corp is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. The company's pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA, a pre-IND gemcitabine prodrug for solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 7
Valuation
Metric | HBPCF |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.50 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | HBPCF |
|---|---|
Quick Ratio | 0.19 |
Current Ratio | 0.19 |
Interest Coverage | −17.69 |
Quick Ratio
HBPCF
Profitability
Metric | HBPCF |
|---|---|
Return on Assets (Normalized) | −13.75% |
Return on Equity (Normalized) | −22.88% |
Return on Invested Capital (Normalized) | −15.35% |
Return on Assets
HBPCF
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|#>@LPK | LOCK|yq?XG | $139B | |||
| Moderna Inc MRNA | LOCK|?@?tc< | LOCK|%F$ | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|ClbQ&@ | LOCK|<@zL> | $94B | |||
| argenx SE ADR ARGX | LOCK|x!fk>N | LOCK|r!< | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!m!lZJ | LOCK|J<b | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|qv<?>VzP | LOCK|Q<!>y | $30B | |||
| Incyte Corp INCY | LOCK|<>?&>B! | LOCK|hd | $24B | |||
| BioNTech SE ADR BNTX | LOCK|TC#W!d | LOCK|q#h | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|^bw>!G | LOCK|B^mDH | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|b!>%?D | LOCK|<YM | $15B |
United States